Wall Street Zen lowered shares of DaVita (NYSE:DVA – Free Report) from a buy rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.
Several other research firms have also weighed in on DVA. Truist Financial lowered their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research note on Friday, August 7th. UBS Group raised their target price on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Oppenheimer set a $220.00 price target on DaVita in a research note on Friday, August 7th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Weiss Ratings cut DaVita from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $233.43.
Read Our Latest Stock Analysis on DVA
DaVita Stock Performance
DaVita (NYSE:DVA – Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. During the same quarter in the previous year, the firm posted $2.95 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts forecast that DaVita will post 14.57 EPS for the current year.
Institutional Investors Weigh In On DaVita
A number of large investors have recently bought and sold shares of the business. Envestnet Portfolio Solutions Inc. bought a new position in DaVita in the 2nd quarter valued at $268,000. Sequoia Financial Advisors LLC boosted its stake in DaVita by 6.2% in the second quarter. Sequoia Financial Advisors LLC now owns 2,791 shares of the company’s stock worth $621,000 after purchasing an additional 164 shares in the last quarter. IPG Investment Advisors LLC bought a new stake in shares of DaVita during the second quarter worth $1,938,000. Integrated Wealth Concepts LLC increased its stake in shares of DaVita by 164.5% in the second quarter. Integrated Wealth Concepts LLC now owns 10,530 shares of the company’s stock valued at $2,343,000 after buying an additional 6,549 shares in the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of DaVita by 66.4% in the second quarter. NewEdge Advisors LLC now owns 361 shares of the company’s stock valued at $80,000 after buying an additional 144 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.
DaVita Company Profile
DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.
DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.
See Also
- Five stocks we like better than DaVita
- Six Flags Launches FlexPay—Is There Any FUN Left in the Stock?
- Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
- Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
- Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
